Valproate Response in Aggressive Autistic Adolescents
Primary Purpose
Autism
Status
Unknown status
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Valproate
Sponsored by
About this trial
This is an interventional treatment trial for Autism focused on measuring Adolescents
Eligibility Criteria
Inclusion Criteria Autism Lives in the Kansas City area Exclusion Criteria Psychoactive maintenance medication Degenerative central nervous system disorder Unstable medical illness Seizures in the 6 months prior to study entry History of valproate sensitivity or previous liver disease History of ovarian cysts Low platelet count or raised liver transaminases
Sites / Locations
- Outpatient MR/Autism Clinic, University of KansasRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00065884
First Posted
August 1, 2003
Last Updated
June 23, 2005
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborators
National Institute of Mental Health (NIMH)
1. Study Identification
Unique Protocol Identification Number
NCT00065884
Brief Title
Valproate Response in Aggressive Autistic Adolescents
Official Title
Valproate Response in Aggressive Autistic Adolescents
Study Type
Interventional
2. Study Status
Record Verification Date
June 2003
Overall Recruitment Status
Unknown status
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborators
National Institute of Mental Health (NIMH)
4. Oversight
5. Study Description
Brief Summary
This study will examine the effect of valproate, a medication used to treat seizures and bipolar disorder, on aggressive behavior in children and adolescents with autism.
Detailed Description
Autism is a complex biological disorder that generally lasts throughout a person's life. It starts before age three and causes delays or problems with many different ways in which a person develops or grows. Some people with autism become very aggressive and can hurt others or themselves. This study will test the hypothesis that aggressive autistic adolescents will show a significantly greater response to valproate maintained at blood levels of 75-100 mcg/ml than to placebo. The study will also assess the safety of valproate in autistic adolescents. This represents the first double-blind study of valproate in mentally retarded/developmentally delayed populations.
Participants in this study will undergo DSM-IV evaluation, the Autism Diagnostic Interview-Revised and Autism Diagnostic Observation Schedule, and baseline blood tests. After baseline screening, all participants will be given a placebo for 1 week. Participants will then be randomized to receive either valproate or placebo for 8 weeks. Dosage adjustment according to blood levels drawn at the end of weeks 2 and 4 will be arranged with parents by a child psychiatrist without breaking the blind. The Aberrant Behavior Check-list-Community (ABC-C) irritability subscale will be the primary measure; the Overt Aggression Scale (OAS), ABC-C hyperactivity subscale, Clinical Global Impressions (CGI) problem severity, Self-Injurious Behavior Questionnaire (SIB-Q), and a valproate side effects checklist will be secondary measures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism
Keywords
Adolescents
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
Double
Allocation
Randomized
Enrollment
30 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Valproate
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Autism
Lives in the Kansas City area
Exclusion Criteria
Psychoactive maintenance medication
Degenerative central nervous system disorder
Unstable medical illness
Seizures in the 6 months prior to study entry
History of valproate sensitivity or previous liver disease
History of ovarian cysts
Low platelet count or raised liver transaminases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jessica A. Hellings, M.D.
Organizational Affiliation
University of Kansas
Official's Role
Principal Investigator
Facility Information:
Facility Name
Outpatient MR/Autism Clinic, University of Kansas
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marilyn Weckbaugh, RN
Phone
913-588-1315
Email
mweckbaugh@kumc.edu
12. IPD Sharing Statement
Learn more about this trial
Valproate Response in Aggressive Autistic Adolescents
We'll reach out to this number within 24 hrs